Rachel Ayres

TL;DR: Current opioid substitution therapy and high‐coverage needle and syringe provision coverage is averting substantial hepatitis C transmission in the United Kingdom and maintaining this coverage while getting current drug injectors onto treatment can reduce incidence by 90% by 2030.

TL;DR: Needle and syringe programmes are a highly effective low-cost intervention to reduce hepatitis C virus transmission, and in some settings they are cost-saving, and are likely to remain cost-effective irrespective of changes in hepatitis Cirus treatment cost and scale-up.

TL;DR: In this paper, a telephone semi-structured interviews were conducted with 28 injecting drug users in Bristol, Southwest of England to examine their experiences relating to the COVID-19 public health measures; changes to opioid substitution therapy (OST) and harm reduction services; and perceived effects of COVID19 on drug use patterns and risk behaviour.

TL;DR: Detachable LDSS are likely to be acceptable and should therefore be offered to those using detachable high dead space syringes and/or fixed 1ml LDSS syringees to inject into deeper femoral veins.

TL;DR: Twenty drug-users aged 55 or over were interviewed about their experience of treatment, barriers to further treatment, and what might encourage participation in the Bristol Drugs Project, and barriers as reluctance to be associated with younger drug users and a sense of shame at ‘still using at this age’ were revealed.